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Human mesoangioblasts are vessel-associated stem cells that are currently in phase I/II clinical trials for the
treatment of patients with Duchenne muscular dystrophy. To date, little is known about the effect of me-
soangioblasts on human immune cells and vice versa. We hypothesized that mesoangioblasts could modulate the
function of immune cells in a similar manner to mesenchymal stromal cells. Human mesoangioblasts did not
evoke, but rather potently suppressed human T-cell proliferation and effector function in vitro in a dose- and time-
dependent manner. Furthermore, mesoangioblasts exert these inhibitory effects uniformly on human CD4+ and
CD8+ T cells in a reversible manner without inducing a state of anergy. Interferon (IFN)-g and tumor necrosis
factor (TNF)-a play crucial roles in the initial activation of mesoangioblasts. Indoleamine 2,3-dioxygenase (IDO)
and prostaglandin E-2 (PGE) were identified as key mechanisms of action involved in the mesoangioblast
suppression of T-cell proliferation. Together, these data demonstrate a previously unrecognized capacity of me-
soangioblasts to modulate immune responses.
Introduction
Human postnatal mesoangioblasts are vessel-associ-ated stem/progenitor cells that are defined by their ex-
pression of pericyte markers and by their capacity to
differentiate predominantly into smooth and skeletal muscle
[1]. Mesoangioblasts can be isolated from mouse, dog, and
adult human tissues [2] and have been demonstrated to
ameliorate signs of muscular dystrophy in both mouse (a-
sarcoglycan-null) [3] and dog (golden retriever muscular
dystrophy) [4] models of muscular dystrophy. To date, me-
soangioblast cell therapy has proved to be themost efficacious
of the many different skeletal muscle stem cell therapies
suggested for Duchenne muscular dystrophy (DMD) [5], as
their ability to cross the vessel walls provides them with a
distinctive advantage compared with the typical skeletal
muscle progenitor cells, satellite cells [5,6]. Currently, human
allogeneic HLA-identical mesoangioblasts are in phase I/II
clinical trial for the treatment of patients with DMD.
A significant hurdle in all allogeneic cell therapies is im-
mune rejection. Indeed, it appears that different cell therapies
evoke varying immune responses which may be due to the
immunogenicity of the cells in question [7–9]. Although al-
logeneic cell therapies are administered in conjunction with
immunosuppression, a greater understanding of the immu-
nogenicity of cell therapies and their influence on the im-
mune response may allow a more tailored therapy that is
geared toward enhancing cell therapeutic efficacy and min-
imizing the immunosuppressive regimen.
DMD is caused by mutations in the dystrophin gene that
lead to muscle fiber degeneration followed by inflammation,
which, in turn, plays a role in disease progression [10]. DMD
onset and progression has been associated with the up-
regulation of inflammatory genes, both in patient samples
[11,12] and in the MDX mouse model [13,14]. Thus, it seems
clear that cell therapies applied to DMD patients will en-
counter a hostile inflammatory environment. In particular,
previous studies have shown that the pro-inflammatory cy-
tokine tumor necrosis factor (TNF)-a is elevated in DMD
patients [15] and also in MDX mice [16]. The presence of such
pro-inflammatory cytokines as well as immune cells present
in damaged and regenerating muscles may directly affect the
therapeutic ability of mesoangioblasts.
A considerable body of data has accumulated, suggesting
that most stem cells display some level of immune privilege
[7,17–19] and in some cases, immunosuppressive capacity
[20–25]. Mesoangioblasts are pericyte-derived cells [1,26] that
share a number of surface markers with mesenchymal
stromal cells (MSC) [27] which are also thought to be of a
perivascular origin [28]. Recently, a study comparing me-
soangioblasts, MSC, and multipotent adult progenitor cells
[27] has revealed that while mesoangioblasts and MSC share
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a number of surface markers, the 2 cell populations are dis-
tinct and have differential transcriptomic gene signatures
that are specific to their functional properties [27]. While
these are important data, this study did not compare the
immunosuppressive functional capacity of these different
cell types. In this study, we sought to examine the immu-
nogenicity of mesoangioblasts in vitro and to characterize the
effects that pro-inflammatory cytokines and exposure to ac-
tivated T cells have on the function of mesoangioblasts and
vice versa. Here, we present novel findings which demon-
strate that human mesoangioblasts do not evoke but rather
significantly inhibit T-cell proliferation through a cell-contact
independent mechanism involving indoleamine 2,3 dioxy-
genase (IDO) and prostaglandin E-2 (PGE-2).
Experimental Procedures
Cell culture
Human mesoangioblasts were isolated from adult skeletal
muscle as previously described [2]. Human mesoangioblasts
were cultured in MegaCell Dulbecco’s modified Eagle medium
(Sigma) containing 5% fetal bovine serum (FBS; PAA), 2mM
glutamine (PAA), 0.1mM b-mercaptoethanol (Gibco-Invitro-
gen), 1% nonessential amino acids (NEAA; Sigma), 5ng/mL
human bFGF (Peprotech, UK), 100 IU mL-1 penicillin and
100mg/mL streptomycin (PAA), and 1% insulin transferrin
selenium X (ITSX) supplement (Gibco-Invitrogen). Alter-
natively, the same cells were cultured in Iscove’s modified
Dulbecco’s medium (PAA) containing 10% FBS, 2mM gluta-
mine, 0.1mM b-mercaptoethanol, 1% NEAA, 5ng/mL human
bFGF, 100 IU mL-1 penicillin, 100mg/mL streptomycin, 1%
ITSX supplement, 0.5mM oleic and linoleic acids (Sigma), 1.5mM
iron [II] chloride tetrahydrate (Fe+ + ; Sigma-Aldrich), and
0.12mM iron [III] nitrate nonahydrate (Fe+ + + ; Sigma-Aldrich).
Human peripheral blood mononuclear cells (PBMCs) were
isolated from buffy coats. All PBMC cultures were carried
out in RPMI 1640 (Sigma-Aldrich) supplemented with 10%
FBS, 1% v/v L-glutamine, 0.05mM b-mercaptoethanol,
100 IU mL - 1 penicillin, and 100mg/mL streptomycin.
T-cell proliferation assays
The proliferation of PBMCs was measured using the 5,6
carboxyfluorescein diacetate succinimidyl ester (CFSE) dilution
assay. PBMCs were labeled with 10mM CFSE in warm phos-
phate-buffered saline (PBS) at room temperature. After 10min,
cells were washed in ice-cold PBS. CFSE-labeled PBMCs
(2.5·105/mL) were then seeded into 96-well round-bottom
plates with or without human CD3/CD28 beads (Dynal-Life
Technologies) (0.5·105/mL) in a total volume of 0.2mL of
complete RPMI 1640. For suppressor assays, mesoangioblasts
were seeded overnight in 96-well round-bottom plates in me-
soangioblast cell culture medium. Medium was then replaced
with complete RPMI 1640 containing PBMC and anti-CD3/
CD28 beads where appropriate. Cells were harvested on days
2, 3, 4, 5, or 6, and CFSE dilution was analyzed by flow cy-
tometry. The actual numbers of CFSE divided cells were cal-
culated using counting beads (BD Biosciences).
Transwell assays
Transwell assays were carried out in 24-well tissue-culture
grade plates (Corning). Mesoangioblasts were seeded out at
6.25 · 104/well overnight as earlier. The medium was then
carefully removed and replaced by complete RPMI 1640.
0.4 mM transwell inserts (Corning) were gently inserted into
the wells, and PBMCs (2.5 · 105/well) +/ - anti-CD3/CD28
beads (0.5 · 105/well) were added directly to the insert. As a
control, PBMC +/ - anti-CD3/CD28 beads were also added
directly to the wells without transwells at the same concen-
trations as described earlier.
Flow cytometric analysis
Mesoangioblasts were characterized for the following
phenotypic surface markers: HLA-ABC, HLA-DR (BD Bio-
sciences), CD105, CD73, CD49b (eBioscience), and CD146
(Biocytex). In addition, mesoangioblast expression of CD40,
CD80, CD86, CTLA-4 (BD Biosciences), and PD-L1
(eBioscience) as well as the HLA molecules were analyzed
before and after stimulation (24 h) with the pro-inflammatory
cytokines interferon (IFN)-g, TNF-a, or interleukin (IL)-1b
(Peprotech). The effect of mesoangioblasts on the expression
of early activation markers on T cells was analyzed by flow
cytometry. Cells were harvested on days 3, 4, 5, and 6 and
stained with anti-CD3, anti-CD25, anti-CD69, and 7AAD.
Intracellular cytokine staining was used to determine the
number of cells producing cytokines in the presence or ab-
sence of mesoangioblasts. On days 3, 4, 5, or 6, cells were
stimulated with phorbol myristate acetate (PMA) (Sigma-
Aldrich) (100 ng/mL) and ionomycin (Sigma-Aldrich)
(1 mg/mL) in the presence of golgi stop (eBioscience) (3 mL/
mL) to block cytokine secretion for 4 h. Cells were then
harvested and stained for surface marker expression of CD3
and 7AAD for 30min at 4C before washing. Subsequently
the cells were fixed/permeabilised using a commercial kit
(eBioscience) for 45min at 4C. After washing, the cells
were blocked in 2% rat serum for 15min followed by
staining with anti-IFN-g and anti-IL-2 antibodies
(eBioscience) for 30min at 4C. The cells were washed and
analyzed by flow cytometry using 7AAD and CD3 to gate
on live T cells. The controls consisted of isotype control
antibodies matched for fluorochrome.
Real-time PCR
Total RNA was isolated from mesoangioblast samples
using an Absolute RNA miniprep kit (Stratagene), and re-
verse transcribed by the AffinityScript Multiple Temperature
Reverse Transcriptase (Agilent Technologies) as previously
described [28]. Real-time quantification was performed using
the ABI Prism 7700 Sequence Detection System (Applied Bio-
systems) using either the fluorogenic probe [PTGS2 (prosta-
glandin-endoperoxide synthase 2)]_Taqman Gene Expression
Assay from Life Technologies, hypoxanthine phosphoribosyl
transferase (HPRT), or the SYBR Green technology (IDO and
HPRT) as previously described [29]. Samples were standard-
ized for HPRT, and quantification of the gene of interest was
given by 2-DCT, where CT is obtained by calculating the dif-
ference between CT of the gene of interest and HPRT.
ELISA
IFN-g, IL-2 (eBioscience) ELISA and PGE-2 competitive
ELISA (R&D Systems) were performed according to the
manufacturer’s instructions.
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Neutralizing and blocking studies
Proliferation assays in the form of [3H]-thymidine incor-
poration or CFSE dilution were carried out as described
earlier in the presence or absence of neutralizing antibodies
to IFN-g (R&D Systems), TNF-a (eBioscience), isotype con-
trol (R&D Systems), or recombinant IL-1 receptor antagonist
(IL-1RA) (eBioscience) at concentrations of 0.5, 1.0, and
2.0 mg/mL. Similarly, inhibitors of IDO; -1-Methyl-L-trypto-
phan (1MT) (Sigma-Aldrich) (0.5mM), Cox-2; indomethacin
(Indo) (Sigma-Aldrich) (10mM), NS-398 (NS3) (Calbiochem)
(0.1, 1.0 mM), inducible nitric oxide synthase (iNOS); L-
NMMA (L-NM) (Sigma-Aldrich) (1mM) and matrix me-
talloproteinases (MMP)-2/9; and SB-3CT (SB3) (Calbiochem)
(6 mM) were utilized in these assays.
Statistical methods
Data were analyzed using the statistical software Prism
(version 5; GraphPad Software) and are reported as
mean – standard error (SE). The unpaired Student’s t-test
was performed to compare 2 mean values. Otherwise, data
were analyzed using a paired Student’s t-test or a two-way
ANOVA with Bonferonni’s post–test, and p-values < 0.05
were considered statistically significant.
Results
Mesoangioblasts fail to induce T-cell
proliferation in vitro
Mesoangioblasts from 3 individuals were characterized by
flow cytometry. All 3 donors shared a similar pattern of
expression of cell surface molecules that was typical of hu-
man mesoangioblasts (Supplementary Fig. S1; Supplemen-
tary Data are available online at www.liebertpub.com/scd).
To determine their immunogenicity, mesoangioblasts were
cocultured with allogeneic CFSE-labeled PBMCs. Me-
soangioblasts did not induce CD3+ T cell proliferation (Fig.
1A) in vitro after 6 days of culture. We hypothesized that the
failure of mesoangioblasts to evoke allogeneic T-cell prolif-
eration may be a consequence of the lack of elements of
antigen presentation machinery by mesoangioblasts. In order
for antigen presentation to take place, foreign peptides are
generated by antigen processing and presented in the context
of HLA molecules. However, mesoangioblasts constitutively
expressed HLA-ABC and low levels of HLA-DR in the
resting state and increased levels after stimulation with the
pro-inflammatory cytokine IFN-g (Fig. 1B). Despite this in-
crease in HLA expression, T-cell proliferation was still not
induced in vitro (Fig. 1C). Thus, T cells were unresponsive to
FIG. 1. Allogeneic meso-
angioblasts fail to induce T-cell
proliferation in vitro. 5,6 carbox-
yfluorescein diacetate succinimi-
dyl ester (CFSE)-labeled
peripheral blood mononuclear
cells (PBMCs) were cultured in
the presence or absence of me-
soangioblasts at varying ratios
[Mesoangioblast: PBMC (1:1 to
1:32)]. CFSE-labeled PBMCswere
stimulated with anti-CD3/CD28
beads (PBMC+B) as a positive
control. On day 6, cells were
harvested and analyzed for CFSE
dilution gating in CD3+ 7AAD-
cells (A). Surface marker expres-
sion of HLA-ABC and DR by
mesoangioblasts before or after
stimulation with interferon
(IFN)-g (20ng/mL)was analyzed
by flow cytometry. Fluor-
ochrome-matched isotype con-
trol antibodies were used as
controls (B). The capacity for
IFN-g prestimulated mesoangio-
blasts to induce T-cell prolifera-
tion was examined as in (A).
Unstimulated or IFN-g stimu-
lated mesoangioblasts (ratio 1:4)
were coculturedwith PBMC for 6
days. CD3+ CFSE-labeled
7AAD- cells were enumerated
using counting beads (C). All ex-
periments were carried out with
at least 3 mesoangioblast and 3
PBMC donors.
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allogeneic mesoangioblasts in vitro even after prestimulation
of the mesoangioblasts with IFN-g.
Characterization of mesoangioblast expression
of HLA, costimulation, and coinhibitory molecules
Efficient activation of T cells requires the expression of
costimulatory molecules. A number of nonprofessional an-
tigen presenting cells that express costimulatory as well as
coinhibitory molecules, and pro-inflammatory cytokines are
known to facilitate the up-regulation of such molecules.
Mesoangioblasts constitutively express neither the costimu-
latory molecules CD40, CD80, and CD86 nor the coinhibitory
molecules CTLA-4 or PD-L1 (Supplementary Fig. S2 and
Fig. 2A). However, the expression of HLA-ABC, HLA-DR,
and PD-L1 and low levels of CD40 were either increased or
induced in mesoangioblasts after stimulation with IFN-g, but
not TNF-a or IL-1b or a combination of the latter. In addition,
combinations of these cytokines did not significantly increase
the expression of these molecules compared with stimulation
with IFN-g alone (Fig. 2). Thus, it seems that under nonin-
flammatory conditions, mesoangioblasts express a hy-
poimmunogenic phenotype, while in the presence of
inflammatory mediators, they display a more immunogenic
phenotype, although induced expression of PD-L1 suggests
that mesoangioblasts have the potential for suppression of
immune responses under inflammatory conditions.
Mesoangioblasts suppress T-cell proliferation
in a dose- and time-dependent manner
Since mesoangioblasts share a similar cell surface pheno-
type and immunogenicity with MSC, we next sought to
determine whether or not mesoangioblasts could exert
FIG. 2. Characterization of mesoangioblast expression of HLA and costimulatory/inhibitory molecules. Mesoangioblasts
were stimulated with IFN-g, tumor necrosis factor (TNF)-a, or IL-1b (20 ng/mL) for 24 h. Cells were trypsinised and washed,
followed by surface staining for HLA-ABC, HLA-DR, CD40, PD-L1, or fluorochrome-matched isotype controls and analysis
by flow cytometry (A). Data are represented as mean – standard error (SE) median fluorescence intensity (MFI) of the
markers examined over 3 different mesoangioblast donors (B–E). (*p < 0.05, **p < 0.01 and ***p < 0.001).
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immune suppressive effects similar to those reported for
MSC. Mesoangioblasts potently suppressed CD3 + T-cell
proliferation in vitro in a dose-dependent manner with sig-
nificant inhibition of T-cell proliferation at ratios of 1:1 to 1:4
(mesoangioblast: PBMC) (Fig. 3A). Robust suppression of T-
cell proliferation independent of the source of the me-
soangioblasts was observed at a ratio of 1:4, and, therefore,
this ratio was selected for further experiments.
Significantly, mesoangioblasts suppressed both CD4 + and
CD8 + T-cell proliferation (Fig. 3B). In addition, the me-
soangioblast inhibition of T-cell proliferation was time de-
pendent with suppression evident on day 4/5 but most
significant on day 6 (Fig. 3C). To determine whether me-
soangioblasts exert their effects immediately or slowly over
time, we carried out a CFSE dilution assay with me-
soangioblasts added to the PBMC cultures on days 0, 2, or 3.
While mesoangioblasts added to the cultures on day 0 re-
duced the level of T-cell proliferation to an average of 12%,
mesoangioblasts added at later times on days 2 and 3 re-
duced proliferation to 50% and 80%, respectively (Fig. 3D).
Together, these results reveal that mesoangioblasts suppress
both CD4 + and CD8 + T-cell proliferation in a dose- and
time-dependent manner.
Anergy is a state of unresponsiveness that can be reversed
by the addition of IL-2. To test the hypothesis that me-
soangioblasts induce T-cell anergy, PBMCs were stimulated
with anti-CD3/CD28 beads in the presence or absence of
mesoangioblasts separated by a transwell. After 6 days, anti-
CD3/CD28 beads were removed, and PBMCs were CFSE
labeled and cocultured with either 1 · 104 or 5· 104 alloge-
neic dendritic cells (DC) in the presence or absence of ex-
ogenous IL-2. PBMCs were harvested on day 5 after the
second-round stimulation and analyzed for CFSE dilution.
PBMCs proliferated in response to allogeneic DC at both
concentrations, regardless of whether or not PBMC were
exposed to mesoangioblasts in the first round (Supplemen-
tary Fig. S3). The addition of exogenous IL-2 resulted in
further increased proliferation of T cells again, irrespective of
the presence of mesoangioblasts in the first round (Supple-
mentary Fig. S3), demonstrating that mesoangioblasts do not
induce a state of anergy in T cells.
Mesoangioblasts inhibit T-cell production
of pro-inflammatory cytokines, but do
not interfere with T-cell activation
The activation markers CD25 and CD69 are rapidly up-
regulated on the surface of antigen-stimulated T cells. To
directly test the effect of mesoangioblasts on the expression
of these early activation markers, PBMCs were stimulated
with anti-CD3/CD28 beads in the presence or absence of
mesoangioblasts. In the presence of mesoangioblasts, while
the number of proliferating cells decreased, the proportion of
cells expressing CD25 and CD69 remained higher relative to
FIG. 3. Mesoangioblasts suppress T-cell proliferation in a dose- and time-dependent manner. CFSE-labeled PBMCs (5· 104/
well) were stimulated with anti-CD3/CD28 beads (1 · 104/well) (P +B) in the presence or absence of mesoangioblasts at
decreasing ratios (mesoangioblast:PBMC). On day 6, cells were harvested and stained with anti-CD3, anti-CD4, anti-CD8,
and 7AAD and analyzed by flow cytometry. CFSE dilution was analyzed in gated CD3 + 7AAD- cells, and the absolute
number of CD3+CFSE dividing cells was enumerated using counting beads (A). Similarly, CFSE dilution was analyzed in
CD3 +CD4 + and CD3 +CD8 + 7AAD - cells (B). A CFSE dilution assay over the entire time course was carried out as described
earlier using a single dose of mesoangioblasts at (1:4) with cells harvested on days 3, 4, 5, and 6. Cells were gated on
CD3 +7AAD -CFSE diluting cells, and the absolute numbers were quantified using counting beads (C). Mesoangioblasts were
added to CFSE-labeled PBMCs stimulated with anti-CD3/CD28 beads on days 0, 2, or 3. CD3 + CFSE diluted cell numbers
were calculated using counting beads and were used to calculate% proliferation (D). All experiments were carried out using a
minimum of 3 mesoangioblast and 3 PBMC donors. (*p < 0.05).
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that observed in PBMC stimulated in the absence of mes-
goangioblasts (Fig. 4A, B). In addition, mesoangioblasts did
not reduce the median fluorescence intensity of CD25 or
CD69 in proliferating T cells, a finding that is consistent
throughout the 4 time points examined (Fig. 4C).
The production of pro-inflammatory cytokines by T cells is
an important effector function. We, therefore, examined the
effect of mesoangioblasts on the intracellular production of
IL-2 and IFN-g by stimulated (anti-CD3/CD28) CD3 + T
cells. Mesoangioblasts significantly inhibited the production
of both IL-2 and IFN-g by CD3+ T cells at the peak of cy-
tokine production on days 4 and 5, respectively (Fig. 4D).
However, mesoangioblasts did not reduce the total produc-
tion of IL-2 or IFN-g, as measured in the supernatants of the
cocultures by ELISA, and, in fact, increased IFN-g concen-
trations (Fig. 4E). These findings highlight the importance of
examining the actual number of cells actively producing
cytokines versus measuring the sum total of cytokine being
produced over time. Taken together, these data suggest that
mesoangioblasts modulate some but not all of the cells
present within the PBMC population.
Cell contact is not required for mesoangioblast
suppression of T-cell proliferation in vitro
Mesoangioblast suppression of T-cell proliferation may be
mediated either through a cell-contact-dependent mecha-
nism or via the production of an immune modulatory solu-
ble factor or factors. Cell contact was not required for
mesoangioblast suppression of T-cell proliferation in vitro
(Fig. 5A, B), and mesoangioblasts that were separated by a
transwell were almost as effective at suppressing T-cell
FIG. 4. Mesoangioblasts inhibit T-cell production of pro-inflammatory cytokines without interfering with T-cell activation.
CFSE dilution assays were performed as earlier in the presence or absence of mesoangioblasts (1:4). Cells were harvested on
days 3, 4, 5, or 6 and analyzed for CFSE dilution and expression of CD25 and CD69. The numbers of CD3 +7AAD - cells
expressing CD25 or CD69 denoted CD25 + or CD69 + (-) or CD25 - or CD69- (,) were calculated using counting beads (A),
and the % of CD25 + and CD69 + cells was calculated from the data in A given earlier and represented in a table format (B).
MFI of CD25 and CD69 were also analyzed over time for PBMCs alone (), PBMCs stimulated with anti-CD3/CD28 beads
(P +B) (-), or in the presence of mesoangioblasts (P +B +Meso) (,) (C). For intracellular cytokine staining, cells were re-
stimulated with phorbol myristate acetate (PMA) (100 ng/mL) and ionomycin (1mg/mL) in the presence of golgi stop (3 mL/
mL) for 4 h on days 3, 4, 5, or 6. Cells were harvested and surface stained for CD3 and 7AAD, fixed, and permeabilized
followed by intracellular staining of IFN-g, IL-2, or matched isotype controls. The number of CD3+ IL-2 + and CD3 + IFN-g +
cells was enumerated using counting beads and is expressed as a function of time (days) for both PBMC + aCD3/28 (,) and
stimulated PBMCs in the presence of mesoangiobalsts (1:4) (-) (D). Total IL-2 and IFN-g were also measured in triplicate
sample supernatants (E) harvested from assays carried out as given earlier in (A). Data are represented as mean– SE. All
experiments were carried out using 2–3 mesoangioblast donors and 2–3 PBMC donors. (*p < 0.05 and **p < 0.01).
MESOANGIOBLASTS MODULATE T CELL FUNCTIONS 517
proliferation as those in direct contact with PBMCs. These
data provide strong evidence for an important role of a
soluble factor in the mechanism of action of mesoangioblasts.
Two key soluble factors known to play a role in immune
modulation and suppression of T-cell proliferation are IDO
and PGE-2 [30,31]. We, therefore, examined the magnitude of
expression of IDO and Cox-2 (an enzyme required for the
production of PGE-2) by mesoangioblasts under basal con-
ditions and after coculture with activated PBMCs or stimu-
lation with IFN-g, TNF-a or IL-1b. Mesoangioblasts do not
constitutively express IDO or Cox-2 mRNA; however, the
expression of both enzymes could be dramatically increased
after coculture with activated PBMC (Fig. 5C). IFN-g, TNF-a,
and IL-1b differentially regulated the expression of IDO and
Cox-2 by mesoangioblasts with IDO induced by IFN-g but
not TNF-a or IL-1b and Cox-2 induced by TNF-a or IL-1b but
not IFN-g (Fig. 5C). The production of PGE-2 by me-
soangioblasts was measured by competitive ELISA and
followed a similar pattern to Cox-2 (Fig. 5C). Significantly,
other pro-inflammatory cytokines, such as IL-6 and TGF-b1,
had no effect (data not shown). Together, these data dem-
onstrate that direct cell-cell contact is not required for me-
soangioblast suppression of T-cell proliferation and provide
evidence for a pivotal role of pro-inflammatory cytokine in-
duction of the immunomodulatory molecules IDO and PGE-
2 by mesoangioblasts.
IFN-c and TNF-a play important roles
in the suppression of T-cell proliferation
by human mesoangioblasts
Since IFN-g, TNF-a, and IL-1b have been identified as im-
portant regulators of the immunomodulatory molecules IDO
and PGE-2 (Fig. 5), we next sought to determine the impor-
tance of these cytokines in mesoangioblast suppression of T-
cell proliferation in vitro. Neutralizing antibodies against IFN-
g and TNF-a at concentrations of 1.0 and 2.0mg/mL but not
0.5mg/mL partially but significantly abolished the inhibitory
effect mediated by mesoangioblasts (Fig. 6A). IL-1RA (1.0mg/
mL) also partially restored proliferation, although the
FIG. 5. Cell contact is not required for mesoangioblast suppression of T-cell proliferation. Transwell assays were set up in
24-well plates with mesoangioblasts seeded overnight. 0.4 mM inserts were gently inserted into wells containing meso-
angioblasts or medium only followed by the addition of CFSE-labeled PBMCs +/ - anti-CD3/CD28 beads. For contact
assays, CFSE-labeled PBMCs +/ - anti-CD3/CD28 beads were added directly to wells containing mesoangioblasts or me-
dium only. Cells were harvested on day 6, and CFSE dilution was analyzed by flow cytometry gating in CD3 +7AAD- cells
(A). The numbers of CD3+ CFSE diluted cells were enumerated using counting beads (B). Mesoangioblasts were cocultured
with PBMCs stimulated with anti-CD3/CD28 beads (P +B) or stimulated with IFN-g, TNF-a, or IL-1b (20 ng/mL) for 24 h.
Cell supernatants were harvested and stored at - 20C before analysis using a PGE-2 competitive ELISA. Cells were lysed for
RNA isolation, cDNA synthesis, and subsequent analysis by real-time PCR for the expression of IDO and Cox-2 relative to the
house-keeping gene hypoxanthine phosphoribosyl transferase (HPRT). Results are expressed as mRNA fold change relative
to HPRT – SE (C). Data are representative of 3 mesoangioblast and PBMC donors and 3 independent experiments. (*p < 0.05,
**p < 0.01 and ***p < 0.001). IDO, indoleamine 2,3-dioxygenase; PGE-2, prostaglandin E-2.
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difference was not significant. In addition, combinations of
IFN-g and TNF-a or all 3 also partially restored T-cell prolif-
eration, but the effect was no greater than when either anti-
IFN-g or TNF-a (2.0mg/mL) was used alone (Fig. 6A).
IFN-g is a key cytokine that is required for the suppression
of T-cell proliferation which is mediated by MSC, and studies
have demonstrated the importance of IFN-g in the activation
of MSC to exert their immunosuppressive effects [32–34].
Moreover, it has been shown that prestimulation of MSC
with IFN-g enhances their immune modulatory capacity
both in vitro and in vivo [33,35]. Given our data demon-
strating that mesoangioblasts require activation by the pro-
inflammatory cytokines IFN-g, TNF-a, and IL-1b to produce
immunomodulatory molecules and to suppress T-cell pro-
liferation, we hypothesized that prestimulation with these
cytokines would enhance mesoangioblast suppression of
T-cell proliferation in vitro. To test our hypothesis, we
stimulated mesoangioblasts with IFN-g, TNF-a, IL-1b, or
combinations of these cytokines for 24 h before adding them
to CFSE dilution assays to examine their immunosuppres-
sive capacity. Prestimulation did not promote the suppressor
capacity of mesoangioblasts, compared with unstimulated
controls, but slightly increased the level of proliferation by
CD3 + T cells (Fig. 6B). However, there was no significant
loss of suppressor capacity by mesoangioblasts after stimu-
lation with pro-inflammatory cytokines.
IDO and PGE-2 play nonredundant roles
in mesoangioblast suppression of T-cell proliferation
Although cell-cell contact was not required for me-
soangioblast suppression of T-cell proliferation, the signifi-
cant increase in PD-L1 expression on mesoangioblasts after
stimulation with IFN-g (Fig. 2) warranted an examination
of the importance of PD-L1 in the mechanism of action of
mesoangioblasts. Neutralizing PD-L1 had no effect on
mesoangioblast suppression of T-cell proliferation (Supple-
mentary Fig. S4).
A number of soluble immunosuppressive factors, includ-
ing IDO [31], PGE-2 [30], iNOS [36], and MMPs [37], have
been demonstrated to modulate T-cell proliferation. To in-
vestigate the relevance of these immunomodulatory soluble
factors in mesoangioblast suppression of T-cell proliferation,
chemical antagonists were added to CFSE dilution assays in
the presence of mesoangioblasts. The addition of 1-Methyl-L-
tryptophan (an inhibitor of IDO) or indomethacin (a Cox-1
and 2 inhibitor) to cultures containing mesoangioblasts par-
tially but significantly restored proliferation, with 1MT
having the most potent effect (Fig. 7A). Importantly addition
of these inhibitors to PBMC in the absencse of mesoangio-
blasts did not interface with PBMC proliferation (Supple-
mentary Fig. S5). The specific Cox-2 inhibitor NS-398
(1.0 mM) restored proliferation to the same extent as indo-
methacin at a concentration of 10 mM (Supplementary Fig.
S6); however, antagonists against iNOS (L-NMMA) and
MMP-2/9 (SB-3CT) had no effect (data not shown). Earlier,
we demonstrated that mesoangioblasts modulate both CD4 +
and CD8 + T-cell proliferation in vitro. To further character-
ize mesoangioblast immunomodulation, we examined the
mechanisms of action involved in the suppression of CD4 +
and CD8+ T cells. Indeed, 1MT and indomethacin restored
the proliferation of both T-cell subsets in part, while the
addition of these antagonists in concert bestowed an additive
effect and completely abolished mesoangioblast suppression
of proliferation in both CD4 + and CD8 + T cells (Fig. 7A, B).
Discussion
Understanding the immunogenicity of allogeneic me-
soangioblasts is critically important if this cell therapy
strategy is to be successfully used to treat patients with
DMD. Previous data have suggested that allogeneic me-
soangioblasts may be immune privileged, although, after
FIG. 6. IFN-g and TNF-a play important roles in meso-
angioblast suppression of T-cell proliferation, but prestimu-
lation with these cytokines does not enhance their effect.
CFSE-labeled PBMCs were stimulated with anti-CD3/CD28
beads in the presence of mesoangioblasts (1:4) and neutral-
izing antibodies against IFN-g and TNF-a or irrelevant iso-
type control antibody (0.5, 1.0, and 2.0 mg/mL) or
recombinant IL-1 receptor antagonist (IL-1RA) (1.0 mg/mL).
Cells were harvested on day 6 and stained with anti-CD3
and 7AAD. After gating on CD3 +7AAD - , the numbers of
CFSE diluting cells were enumerated using counting beads.
Data are represented as mean CD3 + CFSE diluted cell
number – SE (A). Mesoangioblasts were either left untreated
or stimulated with IFN-g, TNF-a, or IL-1b (20 ng/mL) for
24 h before setting up cocultures with CFSE-labeled PBMC
and anti-CD3/CD28 beads. After 6 days, cells were har-
vested and surface stained for CD3 and 7AAD before the
analysis of CFSE dilution. CD3 +CFSE diluted cell numbers
were calculated using counting beads as earlier (B).
(*p < 0.05, **p < 0.01 and ***p < 0.001).
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transplantation in alpha-sarcoglycan null mice, allogeneic
mesoangioblasts or differentiated muscle fibers derived from
mesoangioblasts were found to be more immunogenic [38].
The immunogenicity of mesoangioblasts and the interactions
between these cells and immune cells under inflammatory
conditions require careful investigation. Here, we have
characterized the immunogenicity of human mesoangio-
blasts and have demonstrated that these cells do not evoke
T-cell proliferation in vitro even after prestimulation with IFN-
g, a cytokine likely to be present at the site of implantation,
which results in the increased expression of HLA-ABC,
HLA-DR, and a low level expression of the costimulatory
molecule CD40. Interestingly, IFN-g but not TNF-a or IL-1b
stimulation also induced the expression of PD-L1, an inhib-
itory molecule. Thus, the data suggest that while me-
soangioblasts theoretically have the machinery required for
nonself antigen presentation, they fail to induce allogeneic
T-cell proliferation in vitro, and the expression of PD-L1 may
play a role in facilitating their lack of immunogeneicity.
Next, we investigated the effect of mesoangioblasts on T-cell
proliferation in vitro. For the first time, we show that
mesoangioblasts potently suppress T-cell proliferation
driven by anti-CD3/CD28 stimulation in a dose- and time-
dependent manner. Specifically, mesoangioblasts signifi-
cantly inhibited T-cell proliferation at ratios of 1:1 to 1:4 but
not 1:8. In addition, mesoangioblasts added to stimulated
PBMC cultures on day 0 and day 2 inhibited proliferation
by *80% and 50%, respectively; whereas the addition of
mesoangioblasts on day 3 resulted in *10%–20% suppres-
sion of T-cell proliferation.
Both CD4 + and CD8 + T cells are known to contribute to
the destructive immune response that can be attributed to
allogeneic cells. Significantly, mesoangioblasts were found to
exert their immunosuppressive effect on both CD4 + and
CD8 + T cells, indicating that they have the capacity to pre-
vent an immune attack. Although mesoangioblasts signifi-
cantly inhibited T-cell proliferation, they did not reduce the
number of T cells expressing the early activation markers
CD25 or CD69, a phenomenon also seen with MSC [34].
Nevertheless, a significant decrease in the number of IL-2 +
and IFN-g + T cells after coculture with mesoangioblasts was
observed at the peak of cytokine production. In contrast,
mesoangioblasts did not reduce the total amount of IL-2 and
IFN-g produced over time on days 3, 4, 5, or 6, and it may be
that the proportion of T cells that are not affected (in terms of
proliferation) by mesoangioblasts may compensate and
produce relatively more cytokines. Alternatively, cells other
than T cells within the PBMC population may be responsible
for the differences observed in cytokine production. Inter-
estingly, the suppression of T-cell proliferation induced by
FIG. 7. IDO and PGE-2 are involved in mesoangioblast suppression of T-cell proliferation. CFSE-labeled PBMCs were
stimulated with anti-CD3/CD28 beads (P+B) in the presence of mesoangioblasts (1:4 ratio) with or without inhibitors of IDO
and Cox-2 [1-Methyl-L-trypyophan (1MT) (0.5mM), indomethacin (Indo) (10mM)] or both. On day 6, cells were harvested and
stained with anti-CD3, anti-CD4, anti-CD8, and 7AAD. Cells were gated on live CD4+ or CD8+ populations and analyzed for
CFSE dilution (A), and the numbers of cells undergoing CFSE dilution were enumerated using counting beads (B,C). (*p< 0.05,
**p< 0.01 and ***p< 0.001).
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mesoangioblasts was demonstrated to be reversible, as
PBMCs that were restimulated with alloantigen could pro-
liferate in the absence of IL-2. Collectively, mesoangioblasts
exert their inhibitory effects predominantly at the level of T-
cell proliferation and partially on T-cell effector function with
direct effects on T-cell cytokine production, while T-cell ac-
tivation is spared. Notably, these effects are reversible and
do not involve the induction of T-cell anergy.
Mesoangioblast suppression of T-cell proliferation does
not require cell contact, indicating that soluble factors are the
likely mediators. IDO and PGE-2 have been demonstrated to
play important roles in the immune modulation of MSC [32].
Mesoangioblasts were found to dramatically up-regulate
IDO and Cox-2 and to produce high levels of PGE-2 after
coculture with stimulated PBMCs. Similarly, IDO expression
by mesoangioblasts was induced after stimulation with IFN-
g but not TNF-a or IL-1b. In contrast, Cox-2 expression and
PGE-2 production was induced by TNF-a or IL-1b, but not
IFN-g. Partial but significant restoration of proliferation was
observed in neutralizing studies using anti-IFN-g, anti-TNF-
a, or a combination of these with/without IL-1RA. These
data suggest that IFN-g and TNF-a are indeed key soluble
factors which are involved in the suppression of T-cell pro-
liferation by mesoangioblasts, but other factors may also
play a role. Interestingly, prestimulation with these cytokines
did not enhance mesoangioblast suppression of T-cell pro-
liferation, and while there was no significant difference be-
tween un-stimulated and stimulated mesoangioblasts in
their ability to suppress T-cell proliferation, the number of T
cells proliferating was increased. It is unclear why these
differences exist between mesoangioblasts and MSC with
regard to prestimulation with IFN-g in particular. Perhaps
the key to the differences observed lies in the origin of these 2
cell types (muscle vs. bone marrow) and the types of envi-
ronments that these cells are exposed to.
While an essential role for cell contact was ruled out using
transwell assays, the importance of PD-L1 expression in me-
soangioblasts induced by IFN-g in mesoangioblast suppres-
sion of T-cell proliferation was unclear. Neutralizing studies
demonstrated that PD-L1 was not required for mesoangio-
blast suppression of T-cell proliferation. Nevertheless, the role
of PD-L1 in activated (+ IFN-g) mesoangioblasts remains to be
elucidated. Significantly, the soluble immunomodulatory
factors IDO and PGE-2 were identified as fundamental play-
ers in mesoangioblast suppression of T-cell proliferation. A
combination of both 1MT and indomethacin abolished me-
soangioblast inhibitory effects on T-cell proliferation, and
these data are consistent with studies involving MSC [32].
Conclusion
Overall, we have demonstrated that mesoangioblasts in-
terfere with T-cell proliferation and effector function, a
phenomenon that is reversible. The mechanisms involved
require an initial activation of mesoangioblasts driven by
IFN-g, TNF-a, or IL-1b followed by downstream secretion of
IDO and PGE-2, which mediate the effects observed.
Mesoangioblast cell therapy will encounter an inflamma-
tory milieu in vivo. Evidence suggests that signals arising
from local damage within inflammatory infiltrates attract
mesoangioblasts. Specifically TNF-a and HMGB1 secreted
by inflammatory macrophages have been shown to initiate
mesoangiobalst recruitment [39,40]. Furthermore, it has been
demonstrated that prestimulation of mesoangioblasts with
TNF-a significantly enhances their migration to the site of
muscle damage [41]. We have shown that exposure to pro-
inflammatory cytokines does not significantly impair, but, in
fact, plays important roles in mesoangioblast-mediated
suppression of T-cell proliferation in vitro through the initial
activation of mesoangioblasts and downstream induction of
immunomodulatory soluble factors. Thus, should it prove
necessary to prestimulate mesoangiobalsts with TNF-a to
enhance migration to damaged muscle, the intrinsic immu-
nosuppressive characteristics of mesoangioblasts would not
be impaired. Our data suggest that once recruited to the sight
of muscle damage/degeneration, mesoangioblasts will not
only participate in muscle regeneration but may also en-
hance regeneration and muscle repair through paracrine ef-
fects on immune cells involving the modulation of T-cell
proliferation and effector function. Although the results from
this study are promising, our previous work suggests that
allogeneic mesoangioblasts will be subject to allogeneic re-
jection mechanisms in the absence of immunosuppression
[38]. Data from this previous study demonstrated that allo-
geneic mesoangioblasts engrafted and gave rise to a-Sarco-
glycan expressing muscle fibers in dystrophic mice, and
these fibres were observed for up to 3 months in the absence
of immunosuppression. Significant immune reactivity to the
allogeneic cells was present as measured through in vitro
proliferation assays. However, the level of immune reactivity
was not consistent with the significant engraftment and
survival time of the allogeneic cells. It was hypothesized that
while mesoangioblasts that differentiated and gave rise to
muscle fibers were immunogenic, undifferentiated me-
soangiobalsts exerted some level of immune suppression/
modulation, leading to a prolonged survival time [38]. It
should be noted that immune responses to allogeneic cells
differ between rodents and primates [42], and, thus, results
obtained in mice may not be fully predictive of the fate that
human mesoangioblasts will undergo when transplanted
in vivo. Although we have not examined the immune sup-
pressive capacity of mesoangiobalsts in vivo, the data we
have generated in vitro are consistent with the aforemen-
tioned study, and support the idea that mesoangioblasts may
function in muscle repair on 2 fronts through direct regen-
eration and paracrine effects on the inflammatory environ-
ment. In addition, this study highlights novel potential uses
for mesoangioblasts as an immunomodulatory cell therapy.
Acknowledgments
This research was supported by the European Community
grant OptiStem. Karen English was supported in part by a
Marie Curie Intra-European Fellowship for career develop-
ment. The authors thank Kate Milward and Ou Li for tech-
nical assistance with flow cytometry assays.
Author Disclosure Statement
No competing financial interests exist.
References
1. Dellavalle A, M Sampaolesi, R Tonlorenzi, E Tagliafico, B
Sacchetti, L Perani, A Innocenzi, BG Galvez, G Messina,
MESOANGIOBLASTS MODULATE T CELL FUNCTIONS 521
et al. (2007). Pericytes of human skeletal muscle are myo-
genic precursors distinct from satellite cells. Nat Cell Biol
9:255–267.
2. Tonlorenzi R, A Dellavalle, E Schnapp, G Cossu and M
Sampaolesi. (2007). Isolation and characterization of me-
soangioblasts from mouse, dog, and human tissues. Curr
Protoc Stem Cell Biol Chapter 2:Unit 2B 1.
3. Sampaolesi M, Y Torrente, A Innocenzi, R Tonlorenzi, G
D’Antona, MA Pellegrino, R Barresi, N Bresolin, MG De
Angelis, et al. (2003). Cell therapy of alpha-sarcoglycan null
dystrophic mice through intra-arterial delivery of me-
soangioblasts. Science 301:487–492.
4. Sampaolesi M, S Blot, G D’Antona, N Granger, R Tonlor-
enzi, A Innocenzi, P Mognol, JL Thibaud, BG Galvez, et al.
(2006). Mesoangioblast stem cells ameliorate muscle func-
tion in dystrophic dogs. Nature 444:574–579.
5. Tedesco FS, A Dellavalle, J Diaz-Manera, G Messina and G
Cossu. (2010). Repairing skeletal muscle: regenerative po-
tential of skeletal muscle stem cells. J Clin Invest 120:11–19.
6. Tajbakhsh S. (2009). Skeletal muscle stem cells in develop-
mental versus regenerative myogenesis. J Intern Med
266:372–389.
7. Boyd AS and KJ Wood. (2010). Characteristics of the early
immune response following transplantation of mouse ES cell
derived insulin-producing cell clusters. PLoS One 5:e10965.
8. Swijnenburg RJ, M Tanaka, H Vogel, J Baker, T Kofidis, F
Gunawan, DR Lebl, AD Caffarelli, JL de Bruin, EV Fedo-
seyeva and RC Robbins. (2005). Embryonic stem cell im-
munogenicity increases upon differentiation after
transplantation into ischemic myocardium. Circulation
112:I166–I172.
9. Zhao T, ZN Zhang, Z Rong, and Y Xu. (2011). Im-
munogenicity of induced pluripotent stem cells. Nature
474:212–215.
10. Evans NP, SA Misyak, JL Robertson, J Bassaganya-Riera and
RW Grange. (2009). Immune-mediated mechanisms poten-
tially regulate the disease time-course of duchenne muscular
dystrophy and provide targets for therapeutic intervention.
PM R 1:755–768.
11. Chen YW, P Zhao, R Borup and EP Hoffman. (2000). Ex-
pression profiling in the muscular dystrophies: identification
of novel aspects of molecular pathophysiology. J Cell Biol
151:1321–1336.
12. Evans NP, SA Misyak, JL Robertson, J Bassaganya-Riera and
RW Grange. (2009). Dysregulated intracellular signaling and
inflammatory gene expression during initial disease onset in
Duchenne muscular dystrophy. Am J Phys Med Rehabil
88:502–522.
13. Marotta M, C Ruiz-Roig, Y Sarria, JL Peiro, F Nunez, J
Ceron, F Munell and M Roig-Quilis. (2009). Muscle genome-
wide expression profiling during disease evolution in mdx
mice. Physiol Genomics 37:119–132.
14. Porter JD, S Khanna, HJ Kaminski, JS Rao, AP Merriam, CR
Richmonds, P Leahy, J Li, W Guo and FH Andrade. (2002).
A chronic inflammatory response dominates the skeletal
muscle molecular signature in dystrophin-deficient mdx
mice. Hum Mol Genet 11:263–272.
15. Porreca E, MD Guglielmi, A Uncini, P Di Gregorio, A An-
gelini, C Di Febbo, SD Pierdomenico, G Baccante and F
Cuccurullo. (1999). Haemostatic abnormalities, cardiac in-
volvement and serum tumor necrosis factor levels in X-
linked dystrophic patients. Thromb Haemost 81:543–546.
16. Pierno S, B Nico, R Burdi, A Liantonio, MP Didonna, V
Cippone, B Fraysse, JF Rolland, D Mangieri, et al. (2007).
Role of tumour necrosis factor alpha, but not of cyclo-oxy-
genase-2-derived eicosanoids, on functional and morpho-
logical indices of dystrophic progression in mdx mice: a
pharmacological approach. Neuropathol Appl Neurobiol
33:344–359.
17. BartholomewA,C Sturgeon,M Siatskas, K Ferrer, KMcIntosh,
S Patil, W Hardy, S Devine, D Ucker, et al. (2002). Mesenchy-
mal stem cells suppress lymphocyte proliferation in vitro and
prolong skin graft survival in vivo. Exp Hematol 30:42–48.
18. English K and KJ Wood. (2010). Immunogenicity of em-
bryonic stem cell-derived progenitors after transplantation.
Curr Opin Organ Transplant [Epub ahead of print].
19. Hori J, TF Ng, M Shatos, H Klassen, JW Streilein and MJ
Young. (2003). Neural progenitor cells lack immunogenicity
and resist destruction as allografts. Stem Cells 21:405–416.
20. Ding Y, D Xu, G Feng, A Bushell, RJ Muschel and KJ Wood.
(2009). Mesenchymal stem cells prevent the rejection of fully
allogenic islet grafts by the immunosuppressive activity of
matrix metalloproteinase-2 and -9. Diabetes 58:1797–1806.
21. English K, FP Barry and BP Mahon. (2008). Murine mesen-
chymal stem cells suppress dendritic cell migration, matu-
ration and antigen presentation. Immunol Lett 115:50–58.
22. English K, A French and KJ Wood. (2010). Mesenchymal
stromal cells: facilitators of successful transplantation? Cell
Stem Cell 7:431–442.
23. Highfill SL, RM Kelly, MJ O’Shaughnessy, Q Zhou, L Xia, A
Panoskaltsis-Mortari, PA Taylor, J Tolar and BR Blazar.
(2009). Multipotent adult progenitor cells can suppress graft-
versus-host disease via prostaglandin E2 synthesis and only
if localized to sites of allopriming. Blood 114:693–701.
24. Wang L, J Shi, FW van Ginkel, L Lan, G Niemeyer, DR
Martin, EY Snyder and NR Cox. (2009). Neural stem/pro-
genitor cells modulate immune responses by suppressing T
lymphocytes with nitric oxide and prostaglandin E2. Exp
Neurol 216:177–183.
25. Yachimovich-Cohen N, S Even-Ram, Y Shufaro, J Rachmi-
lewitz and B Reubinoff. (2010). Human embryonic stem cells
suppress T cell responses via arginase I-dependent mecha-
nism. J Immunol 184:1300–1308.
26. Dellavalle A, G Maroli, D Covarello, E Azzoni, A Innocenzi,
L Perani, S Antonini, R Sambasivan, S Brunelli, S Tajbakhsh
and G Cossu. (2011). Pericytes resident in postnatal skeletal
muscle differentiate into muscle fibres and generate satellite
cells. Nat Commun 2:499.
27. Roobrouck VD, C Clavel, SA Jacobs, F Ulloa-Montoya, S
Crippa, A Sohni, SJ Roberts, FP Luyten, SW Van Gool, et al.
(2011). Differentiation potential of human postnatal mesen-
chymal stem cells, mesoangioblasts, and multipotent adult
progenitor cells reflected in their transcriptome and partially
influenced by the culture conditions. Stem Cells 29:871–882.
28. Crisan M, S Yap, L Casteilla, CW Chen, M Corselli, TS Park,
G Andriolo, B Sun, B Zheng et al. (2008). A perivascular
origin for mesenchymal stem cells in multiple human or-
gans. Cell Stem Cell 3:301–313.
29. Carvalho-Gaspar M, JS Billing, BM Spriewald and KJ Wood.
(2005). Chemokine gene expression during allograft rejec-
tion: comparison of two quantitative PCR techniques. J Im-
munol Methods 301:41–52.
30. Harris SG, J Padilla, L Koumas, D Ray and RP Phipps.
(2002). Prostaglandins as modulators of immunity. Trends
Immunol 23:144–150.
31. Mellor AL and DH Munn. (2000). Immunology at the ma-
ternal-fetal interface: lessons for T cell tolerance and sup-
pression. Annu Rev Immunol 18:367–391.
522 ENGLISH ET AL.
32. English K, FP Barry, CP Field-Corbett and BP Mahon. (2007).
IFN-gamma and TNF-alpha differentially regulate im-
munomodulation by murine mesenchymal stem cells. Im-
munol Lett 110:91–100.
33. Prasanna SJ, D Gopalakrishnan, SR Shankar and AB Va-
sandan. (2010). Pro-inflammatory cytokines, IFNgamma and
TNFalpha, influence immune properties of human bone
marrow and Wharton jelly mesenchymal stem cells differ-
entially. PLoS One 5:e9016.
34. Ren G, L Zhang, X Zhao, G Xu, Y Zhang, AI Roberts, RC
Zhao and Y Shi. (2008). Mesenchymal stem cell-mediated
immunosuppression occurs via concerted action of chemo-
kines and nitric oxide. Cell Stem Cell 2:141–150.
35. Polchert D, J Sobinsky, G Douglas, M Kidd, A Moadsiri, E
Reina, K Genrich, S Mehrotra, S Setty, Smith B and Bartho-
lomew A. (2008). IFN-gamma activation of mesenchymal
stem cells for treatment and prevention of graft versus host
disease. Eur J Immunol 38:1745–1755.
36. Hoffman RA, RS Mahidhara, AS Wolf-Johnston, L Lu, AW
Thomson and RL Simmons. (2002). Differential modulation
of CD4 and CD8 T-cell proliferation by induction of nitric
oxide synthesis in antigen presenting cells. Transplantation
74:836–845.
37. Parks WC, CL Wilson and YS Lopez-Boado. (2004). Matrix
metalloproteinases as modulators of inflammation and in-
nate immunity. Nat Rev Immunol 4:617–629.
38. Guttinger M, E Tafi, M Battaglia, M Coletta and G Cossu.
(2006). Allogeneic mesoangioblasts give rise to alpha-sarco-
glycan expressing fibers when transplanted into dystrophic
mice. Exp Cell Res 312:3872–3879.
39. Lolmede K, L Campana, M Vezzoli, L Bosurgi, R Tonlor-
enzi, E Clementi, ME Bianchi, G Cossu, AA Manfredi,
S Brunelli and P Rovere-Querini. (2009). Inflammatory
and alternatively activated human macrophages attract
vessel-associated stem cells, relying on separate HMGB1-
and MMP-9-dependent pathways. J Leukoc Biol 85:
779–787.
40. Palumbo R, BG Galvez, T Pusterla, F De Marchis, G Cossu,
KB Marcu and ME Bianchi. (2007). Cells migrating to sites of
tissue damage in response to the danger signal HMGB1 re-
quire NF-kappaB activation. J Cell Biol 179:33–40.
41. Galvez BG, M Sampaolesi, S Brunelli, D Covarello, M Ga-
vina, B Rossi, G Constantin, Y Torrente and G Cossu. (2006).
Complete repair of dystrophic skeletal muscle by me-
soangioblasts with enhanced migration ability. J Cell Biol
174:231–243.
42. Sachs DH. (2003). Tolerance: of mice and men. J Clin Invest
111:1819–1821.
Address correspondence to:
Prof. Kathryn J. Wood
Transplantation Research Immunology Group
Nuffield Department of Surgical Sciences
University of Oxford
Oxford OX39DU
United Kingdom
E-mail: kathryn.wood@nds.ox.ac.uk
Received for publication July 16, 2012
Accepted after revision August 22, 2012
Prepublished on Liebert Instant Online August 22, 2012
MESOANGIOBLASTS MODULATE T CELL FUNCTIONS 523
